

25 March 2014 EMA/HMPC/307781/2012 Committee on Herbal Medicinal Products (HMPC)

Community herbal monograph on *Eucalyptus globulus* Labill., *Eucalyptus polybractea* R.T. Baker and/or *Eucalyptus smithii* R.T. Baker, aetheroleum

Final

Discussion in Working Party on Community monographs and Community	May 2012
list (MLWP)	September 2012
	November 2012
	March 2013
Adoption by Committee on Herbal Medicinal Products (HMPC) for release	14 May 2012
for consultation	14 May 2013
End of consultation (deadline for comments).	15 November 2013
Rediscussion in Working Party on Community monographs and	January 2014
Community list (MLWP)	January 2014
Adoption by Committee on Herbal Medicinal Products (HMPC)	25 March 2014

Keywords	Herbal medicinal products; HMPC; Community herbal monographs; traditional
	use; Eucalyptus globulus Labill., Eucalyptus polybractea R.T. Baker and/or
	Eucalyptus smithii R.T. Baker, aetheroleum; Eucalypti aetheroleum; Eucalyptus
	oil

BG (bălgarski): Евкалиптово масло	LT (lietuvių kalba): Eukaliptų eterinis aliejus
CS (čeština): blahovičníková silice	LV (latviešu valoda): Eikalipta ēteriskā eļļa
DA (dansk): Eucalyptusolie	MT (malti): Żejt tal-Ewkaliptus
DE (Deutsch): Eukalyptusöl	NL (nederlands): Eucalyptusolie
EL (elliniká): αιθέριο έλαιο ευκαλύπτου	PL (polski): Olejek eteryczny eukaliptusowy
EN (English): Eucalyptus oil	PT (português): Óleo essencial de eucalipto
ES (espanol): Eucalipto, aceite esentcial de	RO (română): ueli volatil de eucalipt
ET (eesti keel): eukalüptiõli	SK (slovenčina): Eukalyptovà silica
FI (suomi): eukalyptusöljy	SL (slovenščina): eterično olje evkalipta
FR (français): Eucalyptus (huile essentielle d')	SV (svenska): Eukalyptusolja
HU (magyar): Eukaliptuszolaj	IS (íslenska):
HR (hrvatska) : Eukaliptusovo eterično ulje	NO (norsk): Eukalyptusolje
IT (italiano): Eucalipto essenza	

Community herbal monograph on *Eucalyptus globulus* Labill., *Eucalyptus polybractea* R.T. Baker and *Eucalyptus smithii* R.T. Baker, aetheroleum

1. Name of the medicinal product

To be specified for the individual finished product.

2. Qualitative and quantitative composition^{1, 2}

Well-established use	Traditional use
	With regard to the registration application of Article 16d(1) of Directive 2001/83/EC as amended
	<i>Eucalyptus globulus</i> Labill., <i>Eucalyptus polybractea</i> R.T. Baker and <i>Eucalyptus smithii</i> R.T. Baker, aetheroleum (Eucalyptus oil)
	i) Herbal substance Not applicable
	ii) Herbal preparations Essential oil

3. Pharmaceutical form

Well-established use	Traditional use
	Herbal preparation in solid or liquid dosage forms for oral use.
	Herbal preparations in liquid dosage forms for inhalation or as bath additives.
	Herbal preparations in liquid or semi-solid dosage forms for cutaneous use.
	The pharmaceutical form should be described by the European Pharmacopoeia full standard term.

¹ The declaration of the active substance(s) for an individual finished product should be in accordance with relevant herbal quality guidance.

 $^{^2}$ The material complies with the Ph. Eur. monograph (ref.: 07/2012:0390).

Community herbal monograph on *Eucalyptus globulus* Labill., *Eucalyptus polybractea* R.T. Baker and/or *Eucalyptus smithii* R.T. Baker, aetheroleum EMA/HMPC/307781/2012

4. Clinical particulars

4.1. Therapeutic indications

Well-established use	Traditional use
	Indication 1)
	Traditional herbal medicinal product used for relief of cough associated with cold. Indication 2)
	Traditional herbal medicinal product for the symptomatic relief of localised muscle pain.
	The product is a traditional herbal medicinal product for use in specified indications exclusively based upon long-standing use.

4.2. Posology and method of administration

Well-established use	Traditional use
	Posology
	Indication 1)
	<u>Oral use</u>
	Adolescents, adults and elderly
	Single dose: 100-200 mg, 2 to 5 times a day
	The use in children under 30 months of age is contraindicated (see section 4.3 'Contraindications').
	The use in children under 12 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	<u>Cutaneous use</u>
	Children between 4 and 12 years of age, adolescents, adults and elderly
	Single dose for liquid dosage forms: a few drops on chest or back, 2 to 3 times daily
	Single dose for semi-solid dosage forms (10% Eucalyptus oil): apply a thin layer on chest and back, 2 to 3 times daily
	The use in children under 30 months of age is contraindicated (see section 4.3

Well-established use	Traditional use
	'Contraindications').
	The use is not recommended in children between 2.5 and 4 years of age (see section 4.4 'Special warnings and precautions for use').
	Inhalation
	Adolescents, adults and elderly
	Single dose: up to 3-8 drops per 250 ml boiling water, 3 times daily
	Children between 4 and 12 years of age
	Single dose: up to 2-4 drops per 250 ml boiling water, 3 times daily
	The use in children under 30 months of age is contraindicated (see section 4.3 'Contraindications').
	The use in children between 2.5 and 4 years of age is not recommended (see section 4.4 'Special warnings and precautions for use').
	Use as bath additive
	Adolescents, adults and elderly
	Single dose: 1.5-6 g essential oil/100 l water, 3 to 4 times a week
	Children between 4 and 12 years of age
	Single dose: 0.5-3 g essential oil/100 l water, 3 to 4 times a week
	Recommended bath temperature is 35-38°C for 10-20 minutes.
	The use in children under 30 months of age is contraindicated (see section 4.3 'Contraindications').
	The use is not recommended in children between 2.5 and 4 years of age (see section 4.4 'Special warnings and precautions for use').
	Indication 2)
	Cutaneous use
	Children between 4 and 12 years of age, adolescents, adults and elderly

Well-established use	Traditional use
	Single dose for liquid dosage forms: a few drops on the affected areas, 2 to 3 times daily
	Single dose for semi-sold dosage forms (10% eucalyptus oil): apply a thin layer on affected areas, 2 to 3 times daily
	The use in children under 30 months of age is contraindicated (see section 4.3 'Contraindications').
	The use is not recommended in children between 2.5 and 4 years of age (see section 4.4 'Special warnings and precautions for use').
	Use as bath additive
	Children between 4 and 12 years of age, adolescents, adults and elderly
	Single dose: 1.7-4 g essential oil/100 l water, 3 to 4 times a week
	Recommended bath temperature is at 35-38°C for 10-20 minutes.
	The use in children under 30 months of age is contraindicated (see section 4.3 'Contraindications').
	The use is not recommended in children between 2.5 and 4 years of age (see section 4.4 'Special warnings and precautions for use').
	Duration of use
	Indication 1)
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Indication 2)
	<u>Use as bath additive</u>
	If the symptoms persist longer than 1 week during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.

Well-established use	Traditional use
	Cutaneous use
	If the symptoms persist longer than 2 weeks during the use of the medicinal product, a doctor or a qualified health care practitioner should be consulted.
	Method of administration
	Oral use (indication 1)
	Cutaneous use (indications 1, 2)
	Inhalation (indication 1)
	Use as bath additive (indications 1, 2)

4.3. Contraindications

Well-established use	Traditional use
	Hypersensitivity to Eucalyptus oil or 1,8-cineol.
	Children with history of seizures (febrile or not).
	Children under 30 months of age, because there is a risk that 1,8-cineole containing preparations, like other essential oils, can induce laryngospasm.
	Full hot baths are contraindicated in cases of large skin injuries and open wounds, acute skin diseases, high fever, severe infections, severe circulatory disturbances and cardiac failure.

4.4. Special warnings and precautions for use

Well-established use	Traditional use
	The use in children between 2.5 and 4 years of age has not been established due to lack of adequate data. Cutaneous use
	Eye contact with unwashed hands after the application of eucalyptus oil may potentially cause irritation.
	Eucalyptus oil should not be applied on broken or irritated skin.
	<u>Oral use</u>

Well-established use	Traditional use
	Eucalyptus oil should be used with caution in inflamed and ulcerated conditions of the gastrointestinal tract.
	Indication 1) When dyspnoea, fever or purulent sputum occurs, a doctor or a qualified health care practitioner should be consulted.
	The oral use in children under 12 years of age has not been established due to lack of adequate data. Indication 2)
	When reddening or swelling of the aching parts occur a doctor or a qualified health care practitioner should be consulted.

4.5. Interactions with other medicinal products and other forms of interaction

Well-established use	Traditional use
	None reported.

4.6. Fertility, pregnancy and lactation

Well-established use	Traditional use
	Safety during pregnancy and lactation has not been established. In the absence of sufficient data, the use during pregnancy and lactation is not recommended. No fertility data available.

4.7. Effects on ability to drive and use machines

Well-established use	Traditional use
	No studies on the effect on the ability to drive and use machines have been performed.

4.8. Undesirable effects

Well-established use	Traditional use
	None known.
	If adverse reactions occur, a doctor or a qualified

Well-established use	Traditional use
	health care practitioner should be consulted.

4.9. Overdose

Well-established use	Traditional use
	Cutaneous use
	Accidental overdose may cause skin irritation.
	Inhalation No case of overdose has been reported.
	Oromucosal use Accidental overdose may cause gastro-intestinal symptoms, vomiting, diarrhoea, nausea, loss of
	consciousness, apnoea, respiratory problems, tachypnea, ataxia and other CNS problems, dilated or constricted pupils.

5. Pharmacological properties

5.1. Pharmacodynamic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.2. Pharmacokinetic properties

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended.

5.3. Preclinical safety data

Well-established use	Traditional use
	Not required as per Article 16c(1)(a)(iii) of Directive 2001/83/EC as amended, unless necessary for the safe use of the product. Adequate tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed.

6. Pharmaceutical particulars

Well-established use	Traditional use
	Not applicable.

7. Date of compilation/last revision

12 March 2014